Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs137852593
rs137852593
AR
0.740 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000

dbSNP: rs137852593
rs137852593
AR
0.740 GeneticVariation UNIPROT

dbSNP: rs137852581
rs137852581
AR
0.720 GeneticVariation BEFREE T can nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer mutation. 17591767

2007

dbSNP: rs137852581
rs137852581
AR
0.720 GeneticVariation BEFREE SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant. 9092797

1997

dbSNP: rs137852581
rs137852581
AR
0.720 GeneticVariation UNIPROT

dbSNP: rs137852571
rs137852571
AR
0.710 GeneticVariation BEFREE In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met. 12507906

2003

dbSNP: rs137852571
rs137852571
AR
0.710 GeneticVariation UNIPROT

dbSNP: rs1340026226
rs1340026226
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852567
rs137852567
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852580
rs137852580
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852582
rs137852582
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852583
rs137852583
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852584
rs137852584
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852591
rs137852591
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs138454018
rs138454018
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs78686797
rs78686797
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs868669253
rs868669253
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002